Lilly rises on vaccine deals
Eli Lilly plans nearly $4 billion in vaccine deals to expand infectious disease research. The move aims to boost the company's presence in the sector.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.